Atypical Antipsychotics — Metabolic Effects

The medication treating a patient's psychosis may quietly be triggering diabetes and cardiovascular disease. Atypical antipsychotics carry metabolic risks that kill more silently than the symptoms they treat.

Second-generation (atypical) antipsychotics — clozapine, olanzapine, quetiapine, risperidone, aripiprazole, ziprasidone — are first-line for schizophrenia and bipolar disorder because they cause fewer extrapyramidal symptoms than typicals. However, their antagonism of H1-histamine and 5-HT2C serotonin receptors drives metabolic syndrome: weight gain, hyperglycemia, dyslipidemia, and insulin resistance. Clozapine and olanzapine carry the highest metabolic risk. Monitoring is non-negotiable: fasting glucose and lipid panel at baseline, 12 weeks, then annually. Weight and waist circumference every visit. HbA1c if glucose trends upward. A client gaining more than 7% of baseline body weight warrants a provider conversation about switching agents. Teach clients to report polydipsia, polyuria, and unexpected weight gain — these are early metabolic red flags. Clozapine also requires absolute neutrophil count (ANC) monitoring for agranulocytosis, a separate but equally critical safety concern unique to that drug.

Key Distinctions

Don't confuse metabolic syndrome from atypicals with EPS from typicals — these are different drug generations with different primary adverse profiles. Students mix up clozapine's agranulocytosis monitoring (ANC/blood draws) with its metabolic monitoring (glucose, lipids, weight) — both are required but for entirely different dangers. Aripiprazole and ziprasidone are considered lower metabolic risk; clozapine and olanzapine are highest.

Clinical Pearl

Cloz-and-Olanz pack on the pounds. Think 'CO' — Clozapine, Olanzapine — as the two heaviest hitters for weight gain and metabolic syndrome.